Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib

Author： Kanazawa Shigenori Yamaguchi Kazuyuki Kinoshita Yoshimi Komiyama Yutaka Muramatsu Mikiko Nomura Shosaku

ISSN： 0171-5216

Source： Journal of Cancer Research and Clinical Oncology, Vol.132, Iss.11, 2006-11, pp. : 719-725

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib

By Wang Fenghua

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 331-335

Humana Press, Inc

Access to resources Recommend Favorite

Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib

Experimental and Therapeutic Medicine, Vol. 2, Iss. 4, 2011-01 ,pp. : 685-693

Spandidos Publications

Access to resources Recommend Favorite

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F Febbo Phillip G

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

A population-based study of gefitinib in patients with postoperative recurrent non-small cell lung cancer

Experimental and Therapeutic Medicine, Vol. 3, Iss. 1, 2012-01 ,pp. : 53-59

Spandidos Publications

Access to resources Recommend Favorite